Overcoming cancer drug resistance

Pipeline

Cancer drug resistance

INVESTORS

Interim report for Q3 2022

Read more

PRESS RELEASES

5 December 2022

Scandion Oncology announces share purchase by incoming President & CEO

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options today announced that the incoming President & CEO has purchased shares in the company.

1 December 2022

Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer

Bringing more than 20 years of experience as a senior level executive in the global pharmaceutical and biotech industry, Francois Martelet will join Scandion Oncology on January 2, 2023.

23 November 2022

Scandion Oncology announces share purchase by member of the Board of Directors

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options today announced that a member of the Board of Directors has purchased shares in the company.

View all press releases

UPCOMING EVENTS

Redeye Fight Cancer

We will give a presentation and update on Scandion followed by a Q&A session.

Year-end report 2022

Annual Report 2022

View all upcoming events

Learn more about our unique first-in-class lead compound SCO-101

Read more about SCO-101

LATEST PRESENTATIONS

28 November 2022

Redeye Life Science Day

Infocus interview with CEO Johnny Stilou at Redeye Life Science Day 2022.

26 October 2022

Økonomisk Ugebrev conference

Watch the presentation by acting CEO and CFO Johnny Stilou.

24 October 2022

BIO-Europe 2022

See the slide deck.

View all presentations

INVESTOR

Scandion Oncology Capital Markets Day

September 8, 2021

Watch the presentations from Scandion Oncology’s Capital Markets Day

Capital Markets Day View all presentations

CAREER

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments